| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 2mg |
|
||
| 5mg |
|
||
| 10mg | |||
| 25mg | |||
| Other Sizes |
| Targets |
ODN-2007 targets Toll-like receptors (TLRs), specifically TLR9. As a class B CpG ODN, it contains a fully phosphorothioated backbone and unmethylated CpG motifs. Activation of TLR9 initiates innate immune signaling pathways, promoting B cell activation and Th1-biased adaptive immunity.
|
|---|---|
| ln Vitro |
ODN 2007 (1 or 5 μg/mL, 3–18 h) strongly increases the expression of interferon IFN-γ and IFN-β in chicken macrophages[1]. ODN 2007 (10 μg/mL, 0.5–12 h) can raise AKT and ERK2 phosphorylation levels and promote NO production[3].
In chicken macrophage MQ-NCSU cells, ODN-2007 (1 or 5 ug/mL, 3-18 h) significantly stimulates IFN-gamma and IFN-beta expression. In HD11 cells, it (10 ug/mL) increases ERK2 and AKT phosphorylation and stimulates NO production. It also upregulates IFN-gamma, IL-6, and MIP-3alpha mRNA levels, demonstrating broad immunostimulatory activity across species. |
| ln Vivo |
Through controlling the expression of genes linked to the immune system in zebrafish infected with Vibrio traumaticus FJ03-X2, ODN 2007 (intraperitoneal injection, 1 μg, once) can improve the immunological response[2].
In zebrafish infected with Vibrio traumatus, intraperitoneal injection of ODN-2007 (1 ug) enhances immune responses, reducing cumulative mortality (15.0% in treated vs. 42.1% in control) and diminishing intestinal immune-related gene expression (e.g., TNF, IFNgamma, IL-1beta, IL-10). It modulates immune system-related genes to combat bacterial infection. |
| Enzyme Assay |
Not applicable. As an oligonucleotide TLR9 agonist, its activity is typically assessed in cell-based assays measuring TLR9 engagement and downstream signaling, rather than through classical cell-free receptor-ligand binding assays.
|
| Cell Assay |
RT-PCR[1]
Cell Types: MQ-NCSU cells (a chicken macrophage cell line) Tested Concentrations: 1 μg/mL, 5 μg/mL Incubation Duration: 3 h, 12 h, 18 h Experimental Results: Dramatically stimulated an increase in transcriptional expression of IFN-γ after 3 hrs (hours) regardless of the dose. Increased the mRNA expression of IL-1β at 5 μg/mL high dose regardless of the time point. Western Blot Analysis[3] Cell Types: HD11, a replication-deficient avian leukemia virus MC29-transformed macrophage-like cell line Tested Concentrations: 10 μg/mL Incubation Duration: 0.5 h, 1 h, 3 h, 6 h, 12 h Experimental Results: Resulted in a significant increase in ERK2 and AKT phosphorylation levels and increased IFN-γ, IL-6 and MIP-3α mRNA levels. Stimulated an increase in the level of NO. MQ-NCSU or HD11 cells are seeded in plates. ODN-2007 is added at 1-10 ug/mL for 3-18 h. Total RNA is extracted, and IFN-gamma, IFN-beta, IL-1beta, IL-6, and MIP-3alpha mRNA are quantified by RT-PCR. For Western blotting, cells are lysed after 0.5-12 h of treatment, and phosphorylated ERK2 and AKT levels are measured using specific antibodies. |
| Animal Protocol |
Animal/Disease Models: Zebrafish infected with Vibrio traumaticus FJ03-X2[2]
Doses: 1 μg Route of Administration: intraperitoneal (ip)injection; once Experimental Results: demonstrated a cumulative mortality rate of 15.0% in treated group while the control group reached 42.1%. demonstrated a significant decrease in the expression levels of all intestinal immune-related genes such as TNF, IFNg1-2, IL-1β, IL-10, especially IL-1β diminished by 99.88%. Zebrafish are infected with Vibrio traumatus FJ03-X2. ODN-2007 (1 ug) is administered via intraperitoneal injection once post-infection. Cumulative mortality is recorded. At the end of the study, intestinal tissues are collected, RNA is extracted, and expression levels of immune-related genes (TNF, IFNgamma1-2, IL-1beta, IL-10) are quantified by qRT-PCR. |
| ADME/Pharmacokinetics |
PK data are limited. ODN-2007 is soluble in H2O (20 mg/mL). It is formulated in endotoxin-free water or PBS for injection. The phosphorothioate backbone provides nuclease resistance. Storage: powder at -20degC for 3 years; in solvent at -80degC for 6 months. Molecular weight: 6852.5.
|
| Toxicity/Toxicokinetics |
Standard safety precautions for oligonucleotides apply. ODN-2007 is for research use only, not for human therapy. Avoid inhalation and contact. Use PPE in a well-ventilated area. The compound may cause immunostimulatory effects.
|
| References |
|
| Additional Infomation |
This is a research-grade TLR agonist. Sequence: DNA, d(P-thio)(T-C-G-T-C-G-T-T-G-T-C-G-T-T-T-G-T-C-G-T-T). It is used to study innate immunity, vaccine development, and host-pathogen interactions. ODN-2007 has been investigated for potential use in allergic asthma and systemic lupus erythematosus.
|
| Molecular Formula |
NA??MOLECULARWEIGHT
|
|---|---|
| Molecular Weight |
0
|
| CAS # |
455348-63-7
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~20 mg/mL (~2.92 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
